NCT06382103View on ClinicalTrials.gov

Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy

RecruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DIAGNOSTIC_TEST

ctDNA monitoring

The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.

DIAGNOSTIC_TEST

Plasma proteomic analysis

plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER